GLP1R and obesity due to melanocortin 4 receptor deficiency: In addition, several emerging GLP-1 medicines simultaneously target receptors for hormones such as GIP, glucagon, and amylin and are currently being evaluated for the treatment of obesity and related metabolic conditions (2–4).